Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

PURPOSE: The addition of immunotherapy, including a combination of anti-GD2 monoclonal antibody (mAb), ch14.18, and cytokines, improves outcome for patients with high-risk neuroblastoma. However, this therapy is limited by ch14.18-related toxicities that may be partially mediated by complement activ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Navid, Fariba, Sondel, Paul M., Barfield, Raymond, Shulkin, Barry L., Kaufman, Robert A., Allay, Jim A., Gan, Jacek, Hutson, Paul, Seo, Songwon, Kim, KyungMann, Goldberg, Jacob, Hank, Jacquelyn A., Billups, Catherine A., Wu, Jianrong, Furman, Wayne L., McGregor, Lisa M., Otto, Mario, Gillies, Stephen D., Handgretinger, Rupert, Santana, Victor M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4017710/
https://ncbi.nlm.nih.gov/pubmed/24711551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.50.4423
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados